ClinConnect ClinConnect Logo
Search / Trial NCT00447525

REVAXIS® Versus DT Polio® as a Second Booster in 6 Year-old Children

Launched by SANOFI PASTEUR, A SANOFI COMPANY · Mar 13, 2007

Trial Information

Current as of April 25, 2025

Completed

Keywords

Prevention Of : Diphtheria, Tetanus And Poliomyelitis

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Healthy child without chronic severe disease of either gender,
  • 2. 6 year-old child on vaccination day,
  • 3. Child previously vaccinated with three doses of a diphtheria, tetanus and poliomyelitis containing vaccine given alone or in combination within the first 6 months of life and a booster dose of a diphtheria, tetanus and poliomyelitis containing vaccine given alone or in combination at 16 - 18 months of life (±2 months),
  • 4. Consent form signed by both parents, or by the legal representative, properly informed about the study.
  • Exclusion Criteria:
  • 1. Child who had received less or more than 4 doses of a diphtheria, tetanus and/or poliomyelitis containing vaccine,
  • 2. Previous clinical or bacteriological diagnosis of diphtheria, tetanus or poliomyelitis,
  • 3. Child who had received any vaccine in the previous 30 days or with a vaccination scheduled during the course of the study,
  • 4. Child who present with immune impairment or humoral/cellular deficiency, neoplastic disease or depressed immunity,
  • 5. Child who had received within the previous 150 days or who will receive during the course of the study, any immunoglobulins or blood derived products,
  • 6. Child with true hypersensitivity to at least one of the components of a study vaccine or to streptomycin, neomycin or polymixin B,
  • 7. Known personal history of encephalopathy, seizure disorder or progressive, evolving or unstable neurological condition,
  • 8. Child who had presented severe hypersensitivity following an earlier immunization against diphtheria and/or tetanus,
  • 9. Known history of thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injection,
  • 10. Acute severe febrile illness and/or oral temperature ≥37.5°C at the time of vaccination

About Sanofi Pasteur, A Sanofi Company

Sanofi Pasteur, a subsidiary of Sanofi, is a global leader in the development and production of vaccines. With a rich heritage in vaccine innovation, the company is dedicated to advancing public health by providing safe, effective, and accessible immunizations for a wide range of infectious diseases. Sanofi Pasteur invests significantly in research and development to address evolving health challenges and to enhance vaccine coverage worldwide. Committed to collaboration with health organizations and communities, the company strives to protect individuals and populations through its comprehensive portfolio of vaccines, contributing to the prevention of diseases and the promotion of healthier lives globally.

Locations

Arras, , France

Nancy, , France

Poitiers, , France

Rouen, , France

Brest, , France

Draguignan, , France

Toulouse, , France

Laon, , France

Annecy, , France

Paris, , France

Caen, , France

Strasbourg, , France

Quimper, , France

Albi, , France

Floirac, , France

Le Havre, , France

Maromme, , France

Nogent Sur Marne, , France

Angers, , France

Clamart, , France

Besancon, , France

Albertville, , France

Anzin, , France

Asnieres, , France

Avion, , France

Bassens, , France

Bersee, , France

Blois, , France

Boulogne, , France

Broglie, , France

Chalon En Champagne, , France

Champdeniers, , France

Chigny Les Roses, , France

Cholet, , France

Claix, , France

Collombey Les Belles, , France

Enghien Les Bains, , France

Frouard, , France

Haguenau, , France

Illkirch Graffenstaden, , France

Issy Les Moulineaux, , France

La Neuville Roy, , France

Les Pieux, , France

Louverne, , France

Louvigne De Bais, , France

Manduel, , France

Marcq En Barouel, , France

Marseille, , France

Miniac Morvan, , France

Montpellier, , France

Montsang/Orge, , France

Morangis, , France

Nantes, , France

Ostwald, , France

Plouzane, , France

Pont A Mousson, , France

Saint Sebastien Sur Loir, , France

Saint Ouen, , France

Saint Raphael, , France

Sanary Mer, , France

Sevres, , France

Villemomble, , France

Patients applied

0 patients applied

Trial Officials

Medical Director

Study Director

Sanofi Pasteur, a Sanofi Company

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials